Air Street Capital

Investment arm of Enterprise Singapore, nurturing Singapore-based tech startups with intellectual property and global market potential. SEEDS Capital was founded in 2001 to foster entrepreneurship in Singapore when the technology and startup ecosystem was nascent. Today, Singapore is ranked first in Asia and seventh globally in Startup Blink’s Global Startup Ecosystem Index 2022. SEEDS is one of the most active investors in Singapore according to Tech In Asia. As the investment arm of Enterprise Singapore, SEEDS catalyses private sector investments into Singapore-based, early-stage technology startups that are pioneering scientific and engineering solutions. We co-invest with institutional investors such as venture capital funds (VCs), corporate venture capital arms (CVCs) and family offices in innovative startups with strong intellectual content and global market potential. As early-stage investors, we invest in the first and second institutional rounds of technology startups. Our focus sectors are Advanced Manufacturing & Engineering, Health & Biomedical Sciences and Urban Solutions & Sustainability. We also look at emerging areas such as Agri-tech, Artificial Intelligence, Blockchain, Quantum and Space Technologies. Post-investment, we leverage Enterprise Singapore’s network across industries and global overseas centres to add value to our portfolio companies. Since 2017, we have deployed more than S$220 million and stimulated more than S$950 million of private sector investments into more than 160 companies. Learn more about our co-investment partners and portfolio startups.

We are at the forefront of revolutionary technologies disrupting industries and transforming human life at an accelerating pace towards singularity. Like the high-performance racing teams of Formula 1, we compete to lead premier investments in the world's most exceptional unicorns - hence «Frontline One»

We help technical founders solve their hardest operational and commercialization challenges - all with an eye towards building durable, generational companies. We invest $500K-1M and frequently lead or co-lead. We invest from incorporation to seed stage, with more than 80% of our investments at pre-seed or earlier. Investing in two areas: biological platforms and applied robotics. Biological platforms encompass everything from material science to synthetic biology to AI for drug discovery. Applied robotics includes autonomy, chemical automation, swarm robotics systems, and biomanufacturing, among many others. Our North Star We believe there is a better way. Scientific and technological innovation drive our civilization forward, but the impact of these innovations is muted if they aren’t translated into real world projects. Too many times we’ve seen real scientific breakthroughs curtailed - or their impact delayed - not because of lack of rigor or founder ability, but because the infrastructure and tools don’t exist to commercialize these innovations in a repeatable manner. While scientific founders are sometimes able to raise early capital based on their technology or their backgrounds, the path between that initial funding and their first institutional round is maddeningly unclear and often treacherous. The entrepreneurs who do make it through that gauntlet often need to raise multiple rounds of dilutive capital to get there - stumbling in the dark until they understand what milestones they need to unlock that subsequent financing and build a successful business. Our North Star is helping entrepreneurs commercialize their breakthrough to build durable, impactful, and ultimately generational companies. Our team has founded, invested, and advised deep tech companies for over a decade. We’ve experienced the recessions, the hype cycles, the breakthroughs, and the breakouts. We’ve seen all of the many ways that deep tech companies can fail, but we’ve also seen founders beat the odds and build historic companies, legacies, and movements. It is our greatest privilege to partner with these entrepreneurs.

InVitro Capital is a venture studio that creates, builds, and exits companies in the AI and B2B space. With a primary focus on Healthcare and SaaS, Invitro has developed a unique recipe to de-risk startup innovation and help aspiring exceptional entrepreneurs identify and capitalize on promising opportunities. At InVitro, we believe that the best startups are built by teams with deep domain expertise and a passion for solving real-world problems. That's why we invest in and partner with entrepreneurs who have a proven track record of success and a vision for the future. We provide our portfolio companies with the operational muscles and support they need to succeed, including: Seed funding. Access to our network of mentors and advisors. Expertise in tech, marketing, sales, and business development. Help with go-to-market strategy. We also have a unique approach to exits. Instead of waiting for a large tech company to come knocking, we actively work with our portfolio companies to develop and execute their own exit strategies. This allows us to maximize returns for our investors and give our entrepreneurs the freedom to pursue their next big idea

RA Capital Management is a multi-stage investment manager dedicated to company formation and evidence-based investing in healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools. The firm’s portfolio of private and public companies spans the globe and most therapeutic areas across all stages from discovery through commercialization. We are committed to fostering diversity at RA, in our portfolio companies, and in the broader biotech community. Who We AreOur flexible strategy allows us to provide seed funding to startups and lead private, IPO, and follow-on financings for our portfolio companies, thereby driving value creation from idea inception through commercialization. At RA Capital’s core is its TechAtlas research division, a scientifically trained team that maps out competitive landscapes to put data into context, identify breakthroughs, and originate conviction in new ideas. TechAtlas provides market intelligence and, technical diligence, and other resources to both our internal Investment Team and our portfolio companies. The team’s understanding of industry best practices is derived from an extensive collection of case studies documenting the impact of clinical trial design, partnership structures, and public market dynamics. Beyond CapitalRA Capital offers its portfolio companies much more than capital to help them grow, make decisions, and succeed. We:Serve on boards of private and public companies and host board meetings at our offices Help recruit executives and board members Provide access to TechAtlas maps and expertise Prioritize indications and targets based on their feasibility and value given current scientific knowledge, unmet needs, and emerging competition Monitor for new applications and complementary technologies Create custom maps that lay out a company’s competition and unrealized opportunities Provide extra analytical bandwidth across our large team (e.g., analyze literature, provide insights from scientific and investor conferences) Assist with grant writing and preparation of scientific publications Interview clinicians and key opinion leaders (KOLs) Host advisory boards Facilitate partnership or acquisition discussions with larger companies Help design (or redesign) a corporate slide deck or website, leveraging in-house writing and graphics teams Make introductions to other investors Anchor subsequent financings and set the pace for closing Help select bankers for financings and M&A We also provide a growing suite of Innovator Resources to the broader ecosystem, with more hands-on support for our portfolio companies, management teams, and boards. These resources include: a comprehensive reference guide to conducting successful biotech board meetings; a data-driven guide to how to conduct a logical IPO based on first principles of price discovery and shareholder alignment; and a roadmap for how to convey your company’s unique Equity Value Proposition to employees (because they are also your investors). We’re available to coach you through a pitch, provide feedback on a deck, and partner with you to refine strategy or messaging at every stage. Additionally, we helped to found and continue to support No Patient Left Behind, a non-profit dedicated to promoting affordability of today’s medicines and the development of better ones. More specifically, NPLB advocates for insurance reforms that would allow all patients to afford the treatments they need, draws attention to the full societal value of all medicines and the merits of ensuring that all drugs go generic without delay, and educates lawmakers and the public about the workings of the biomedical ecosystem to protect it against misguided policies. Translation & HuntingRA Capital offers Executive-In-Residence (EIR) and venture partner programs for experienced professionals seeking thought partners. We welcome experienced drug hunters searching for technologies/candidates and looking to start new companies to collaborate with our team, explore the capabilities of our in-house incubator, and take advantage of the breadth and depth of our TechAtlas platform. RAVen, our in-house incubator, provides a collaborative platform for drug hunters and company builders to explore both the novel and the re-imagined. Discoveries and improvements in chemistry, molecular and cellular biology, and materials science create novel capabilities that may address unsolved challenges. Our understanding of fundamental biology is constantly evolving, revealing new applications for existing technologies and partially-developed drug candidates. Programs we consider worthwhile may form the basis for a new venture. We believe that when a business proposition is framed correctly, the capital markets have adequate resources and understanding to fund proper experimental design and solution development without forcing companies to cut corners. Furthermore, we have collaborated extensively with other funds that share our philosophy to enable ambitious and capital-intensive endeavors. Our ValuesWe at RA Capital are introspective and deliberate about the ways in which we engage with each other and those outside our firm. Our values represent a set of clear parameters by which we create working relationships founded on trust, collaboration, diligence, and integrity.We originate conviction. We do not borrow it from others. We expect and strive to inspire the best in everyone. We embrace the unfamiliar. We do not let convention stand in the way of what is right. We learn collaboratively. We have a bias for action. We are persistently curious and humbled by what is left to learn. We are data-driven and challenge assumptions. We preserve the ability to change our mind. We admit our mistakes and share lessons learned. We address the elephant in the room. We value our relationships and are positive, respectful, and open-minded. We take fun seriously.

Fosun RZ Capital was founded in 2013. As a leading industry investment institution with a global layout and unique resources, Fosun RZ Capital focuses on investment in deep tech, AI, fin-tech, healthcare, e-commerce, logistics and travel industries. It is built to empower the globalization of innovative start-ups with its indispensable industry resources in the four major business sectors of Fosun including health, happiness, wealth and smart manufacturing. Fosun RZ Capital is always empowering and evolving together with companies globally. Fosun RZ Capital is committed to becoming an essential investor of global business leaders in the era of technology business innovation. Fosun RZ Capital covers cutting-edge technological innovation in the United States and Israel and high-growth emerging markets in China, India, and Southeast Asia, creating an influential global industry-wide innovation ecosystem. It has a long-term focus on investment in high-growth, high-tech companies in significant economic growth regions worldwide.